On May 8, 2025, Tectonic Therapeutic announced its financial results for the first quarter ended March 31, 2025. The company reported a fortified cash position, projecting over 3 years of cash runway, which provides substantial financial stability for its operations.
Tectonic confirmed plans to share the complete data set from the 19 patients with PH-HFpEF enrolled in Part A of its Phase 1b trial of TX45 at the ESC Heart Failure 2025 Congress. This complete data set is expected to further validate the program's potential.
Looking ahead, the company expects to present topline results from Part B of the Phase 1b trial in the second half of 2025. The Phase 1b data are believed to support both the selected endpoints and patient population for the ongoing APEX Phase 2 trial, providing strong proof-of-principle for the TX45 program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.